Video

Novel Therapy Shows Promise in Group of Patients with Metastatic Colon Cancer

Author(s):

Jamie Cesanek
Conference|ASCO Annual Meeting

Responses to the study drug, according to one of the study’s authors, appeared far superior than what would have been expected with other treatments in patients with HER2-expressing metastatic colorectal cancer.

Patients with HER2-expressing metastatic colorectal cancer appeared to achieve durable and promising results after treatment with trastuzumab deruxtecan (T-DXd), according to recent findings.

Moreover, data from the phase 2 study, which were presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated that treatment with the antibody-drug conjugate was safe with only 13 patients having to discontinue treatment as a result of side effects.

In an interview with CURE®, study author Dr. Kanwal P.S. Raghav, an associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, discussed why the results of this trial are pivotal for this patient population.

“It's a very well-tolerated treatment. And it showed us very robust and promising response rates,” said Raghav. “So what we did see is that our overall survival, progression-free survival as well as response from this therapy in this population appeared to be far superior to what would have been expected from other treatments that these patients would have gotten.”

Transcription:

This study is very pivotal in the sense that it showed us that trastuzumab deruxtecan, which is an antibody drug conjugate – so it's a HER2 antibody, which is attached to a very potent chemotherapy. And it delivers this in a very targeted fashion only to the colon cancer or the tumor cells. Thereby it limits systemic toxicity, or side effects from this drug. So it's a very well-tolerated treatment. And it showed us very robust and promising response rates. So what we did see is that our overall survival, progression-free survival as well as response from this therapy in this population appeared to be far superior to what would have been expected from other treatments that these patients would have gotten.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of woman with black hair.
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Image of Dr. Minesh Mehta at ASCO 2024.
Image of a woman with blond hai
Image of a man with rectangular glasses and short dark hair.
Related Content
Image of COVID-19 cells.
November 18th 2024

COVID-19 RNA May Be Linked to Metastatic Cancer Regression

Ashley Chan
RNA from the COVID-19 infection in patients with certain metastatic cancers may be associated with tumor shrinkage, but more research is necessary.
Teri Greige with medals
February 16th 2023

The Sport of Cancer: How One Survivor Linked Ironman Training and Colorectal Cancer

Brielle Benyon
Teri Griege completed an Ironman triathlon in 2009, and less than a month later received a stage 4 colorectal cancer diagnosis. In this episode of Cancer Horizons, she shared her story.
Woman putting on compression stockings on swollen feet affected by lymphedema condition: © Julia - stock.adobe.com
November 13th 2024

Lymphedema Myths and Misconceptions, From Exercise to Blood Draws

Alex Biese
An expert explains how attitudes towards lymphedema risk have evolved over the years.
‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC
January 27th 2022

‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a woman living with colorectal cancer who was diagnosed 14 years ago at age 29 discusses what it was like to be the youngest person in the treatment room, and how she found another community of young survivors.
"FDA" text.
November 9th 2024

FDA Approves MI Cancer Seek as Companion Diagnostic for Adult and Pediatric Patients With Cancer

Ryan Scott
MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from treatment with targeted therapies.
Image of a cartoon colon with a stethoscope around it on a pink background.
November 8th 2024

James Van Der Beek Opens Up About Colorectal Cancer, U.S. Congressman Reveals Cancer Diagnosis and More

Ashley Chan
From James Van Der Beek spreading awareness about colorectal cancer at a younger age to Gerry Connolly’s recent esophageal cancer diagnosis, here’s what’s happening in the cancer space this week.